

Optimizing Public-Private Partnerships for Clinical Cancer Research: A Workshop October 17-18, 2023

National Cancer Policy Forum

Forum on Drug Discovery, Development, and Translation

[Workshop Website](#)

Lecture Room

NAS Building

2101 Constitution Avenue, NW

Washington, DC 20418



WORKSHOP AGENDA

TUESDAY, OCTOBER 17, 2023 EASTERN TIMEZONE	
7:30 am	Breakfast and Registration (30 minutes)
8:00 am	<p>Session 1: Rationale and Objectives for Public-Private Partnerships in the Clinical Cancer Research Enterprise (2 hours)</p> <p><i>Co-Moderators:</i> Roy Herbst, Yale University Richard L. Schilsky, University of Chicago</p> <p>Welcome and Introductory Remarks (20 minutes)</p> <ul style="list-style-type: none"> Roy Herbst, Yale University Richard L. Schilsky, University of Chicago <p>Keynote Presentations (30 minutes – 15 minutes each)</p> <ul style="list-style-type: none"> Julie Gerberding, Foundation for the National Institutes of Health Dinah Singer, National Cancer Institute <p>Industry Perspective (10 minutes)</p> <ul style="list-style-type: none"> Aida Habtezion, Pfizer Inc. (<i>participating virtually</i>) <p>Patient Advocacy Perspective (10 minutes)</p> <ul style="list-style-type: none"> Ellen Sigal, Friends of Cancer Research <p>Food and Drug Administration Perspective (10 minutes):</p> <ul style="list-style-type: none"> Richard Pazdur, FDA Oncology Center of Excellence <p>Panel Discussion (40 minutes) Includes speakers and:</p> <ul style="list-style-type: none"> Gail Eckhardt, Baylor College of Medicine William Dahut, American Cancer Society, Inc.
10:00 am	Break (15 minutes)

<p>10:15 am</p>	<p>Session 2: Exemplars of Public-Private Partnerships in Clinical Cancer Research (2 hours) <i>Co-moderators:</i> <i>Edith Perez, Mayo Clinic and Bolt Biotherapeutics</i> <i>Heidi Smith, Novartis Pharmaceuticals</i></p> <p>Examples of past and ongoing public-private collaborations in oncology</p> <ul style="list-style-type: none"> • Lung Cancer Master Protocol (LungMAP) (10 minutes) <ul style="list-style-type: none"> ◦ Roy Herbst, Yale University • PALbociclib CoLLaborative Adjuvant Study (PALLAS) (20 minutes) <ul style="list-style-type: none"> ◦ Erica Mayer, Dana-Farber Cancer Institute (<i>participating virtually</i>) ◦ Prash Gopalakrishna, Pfizer Inc. (<i>participating virtually</i>) • Pragmatica-Lung Cancer Treatment Trial (20 minutes) <ul style="list-style-type: none"> ◦ Karen L. Reckamp, Cedars Sinai ◦ Harpreet Singh, FDA Oncology Center of Excellence <p>Panel Discussion (1 hour 10 minutes) Includes speakers and:</p> <ul style="list-style-type: none"> • Stacey Adam, Foundation for the National Institutes of Health • Janet Dancey, Canadian Cancer Trials Group (<i>participating virtually</i>) • Vassilis Gelfinopoulos, European Organisation for Research and Treatment of Cancer (<i>participating virtually</i>) • Meg Mooney, National Cancer Institute • Gwen Nichols, Leukemia and Lymphoma Society
<p>12:15 pm</p>	<p>Lunch (45 minutes)</p>
<p>1:00 pm</p>	<p>Session 3: Regulatory and Policy Considerations for Public-Private Partnerships for Clinical Cancer Research (2 hours 10 minutes) <i>Co-moderators:</i> <i>Gideon Blumenthal, Merck</i> <i>Esther Krofah, Milken Institute and FasterCures</i></p> <p>National Clinical Trials Network (NCTN) Perspectives on Public-Private Partnerships for Cancer Research (10 minutes)</p> <ul style="list-style-type: none"> • James Doroshow, National Cancer Institute <p>FDA Perspective on Optimal Planning, Conduct, and Submission of Registration Intent Trials Conducted Through Public-Private Partnerships (10 minutes)</p> <ul style="list-style-type: none"> • Harpreet Singh, FDA Oncology Center of Excellence <p>Academia/Government Taskforce Perspective: How to Enhance Cooperation Between Agencies and Academia (10 minutes)</p> <ul style="list-style-type: none"> • Michael Morris, Memorial Sloan Kettering Cancer Center <p>Non-Profit Perspective: Patient Centeredness in Clinical Trial Design (10 minutes)</p> <ul style="list-style-type: none"> • Stacie Lindsey, Cholangiocarcinoma Foundation <p>Investor Perspective on Public-Private Partnerships for Cancer Research (10 minutes)</p> <ul style="list-style-type: none"> • Josh Bilenker, Treeline Biosciences

	Panel Discussion (1 hour 20 minutes) Include speakers and: <ul style="list-style-type: none"> • Jeff Allen, Friends of Cancer Research • Charles Blanke, Oregon Health & Science University • John Byrd, University of Cincinnati • Gail Eckhardt, Baylor College of Medicine
3:10 pm	Break (15 minutes)
3:25 pm	Session 4: Enhancing Data Sharing for Public-Private Partnerships for Clinical Cancer Research (2 hours 5 minutes) <i>Co-moderators:</i> Otis W. Brawley, Johns Hopkins University Kristen Rosati, Coppersmith Brockelman PLC Introduction (14 minutes) <ul style="list-style-type: none"> • Otis W. Brawley, Johns Hopkins University (7 minutes) • Kristen Rosati, Coppersmith Brockelman PLC (7 minutes) The Role of Government in Data Sharing (7 minutes) <ul style="list-style-type: none"> • Penny Burgoon, National Institutes of Health The Role of the Research Institution in Data Sharing (7 minutes) <ul style="list-style-type: none"> • Barbara Bierer, Harvard University The Role of the Patient in Data Sharing (14 minutes) <ul style="list-style-type: none"> • The Role of the Patent Advocate (7 minutes) <ul style="list-style-type: none"> ◦ Gwen Nichols, Leukemia and Lymphoma Society • The Role of Health IT in Data Sharing (7 minutes) <ul style="list-style-type: none"> ◦ Deven McGraw, Invitae/Citizen The Role of the Sponsor in Data Sharing (7 minutes) <ul style="list-style-type: none"> • Geoffrey Oxnard, Loxo Oncology, Eli Lilly The Role of the Funder in Data Sharing (7 minutes) <ul style="list-style-type: none"> • Tony Hickson, Cancer Research UK/Cancer Research Horizons The Role of Publications in Data Sharing (14 minutes) <ul style="list-style-type: none"> • Eric Rubin, New England Journal of Medicine (<i>participating virtually</i>) • Kirsten Bibbins-Domingo, Journal of the American Medical Association (<i>participating virtually</i>) Panel Discussion: Solutions for Facilitating Data Sharing (55 minutes)
5:30 pm	Adjourn Day 1
	Reception
WEDNESDAY, OCTOBER 18, 2023 EASTERN TIMEZONE	
7:30 am	Breakfast and Registration (30 minutes)
8:00 am	Session 5: Embedding Clinical Cancer Research in Health Care Delivery (2 hours) <i>Co-moderators:</i> Neal Meropol, Flatiron Health Lawrence Shulman, University of Pennsylvania Abramson Cancer Center

	<p>Community Based Research Consortia (30 minutes)</p> <ul style="list-style-type: none"> • Industry-Sponsored Consortium <ul style="list-style-type: none"> ◦ Melissa Johnson, Sarah Cannon Research Institute (<i>participating virtually</i>) • NCI Community Oncology Research Program Consortium <ul style="list-style-type: none"> ◦ Carolyn Y. Muller, University of New Mexico • American Society of Clinical Oncology Consortia <ul style="list-style-type: none"> ◦ Elizabeth Garrett-Mayer, American Society of Clinical Oncology <p>Challenges and Opportunities for Public-Private Partnerships to Improve Access to Cancer Drugs and Reduce Outcome Disparities in Resource-Constrained Settings (10 minutes)</p> <ul style="list-style-type: none"> • Larry Shulman, University of Pennsylvania Abramson Cancer Center <p>Public-Private Partnerships to Support Post-Marketing Clinical Research in Routine Care Settings (10 minutes)</p> <ul style="list-style-type: none"> • Neal Meropol, Flatiron Health <p>Considerations for Industry Partnerships in Support of Health Care Delivery Research (10 minutes)</p> <ul style="list-style-type: none"> • Craig Tendler, Johnson and Johnson (<i>participating virtually</i>) <p>Panel Discussion (1 hour) Include speakers and:</p> <ul style="list-style-type: none"> • Matthew Cooney, Tempus
10:00 am	Break (15 minutes)
10:15 am	<p>Session 6: Opportunities to Advance Progress in Public-Private Partnerships for Clinical Cancer Research (1 hour, 5 minutes)</p> <p><i>Co-Moderators:</i> Roy Herbst, Yale University Richard L. Schilsky, University of Chicago</p> <p>Panelists: Session 1: Roy Herbst and Richard L. Schilsky Session 2: Edith Perez and Heidi Smith Session 3: Gideon Blumenthal and Esther Krofah Session 4: Otis W. Brawley (<i>participating virtually</i>) and Kristen Rosati Session 5: Neal Meropol and Lawrence Shulman</p>
11:20 am	<p>Wrap-Up/Concluding Remarks (10 minutes)</p> <p><i>Planning Committee Co-Chairs:</i> Roy Herbst, Yale University Richard L. Schilsky, University of Chicago</p>
11:30 am	Adjourn